Clinical trials: Myeloma
Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
Beta Alethine in Treating Patients With Myeloma
RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00006466
- Testing
- beta alethine
- Where
- 3 sites in United States
- Sponsor
- LifeTime Pharmaceuticals
Multiple Myeloma
Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.
The purpose of this study is to measure the markers related to bone metabolism before and after the use of bortezomib injection in patients with multiple myeloma and to evaluate the effect bortezomib injection has on bone disease.
- Trial name
- NCT01026701
- Testing
- bortezomib
- Volunteers
- 104 people
- Sponsor
- Janssen Korea, Ltd., Korea
Multiple Myeloma
A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma
The purpose of this study is determination of the event-free survival with and without Bortezomib consolidation therapy from the day of the first chemotherapeutic, myeloma-specific therapy measure, up to the occurrence of…
- Trial name
- NCT00416273
- Testing
- Bortezomib, No intervention
- Where
- 38 sites in Germany
- Volunteers
- 217 people
- Sponsor
- Janssen-Cilag G.m.b.H
Multiple Myeloma
Examination of Trends in Multiple Myeloma Trial Patient Experiences
Historically, participation in clinical trials has been highly skewed towards specific demographic groups. However, research identifying which trial attributes impact participation, in either positive or negative ways, is…
- Trial name
- NCT05860179
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Multiple Myeloma
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
This is an open-label Phase 1/2a study which will enroll patients that have relapsed or relapsed-refractory multiple myeloma to combination regimens of melflufen with currently approved agents.
- Trial name
- ANCHOR (NCT03481556)
- Testing
- Melphalan flufenamide (Melflufen), Dexamethasone, Bortezomib
- Where
- 16 sites in United States, Czechia and 2 more
- Volunteers
- 56 people
- Sponsor
- Oncopeptides AB
Multiple Myeloma
Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma
STR (Skeletal Targeted Radiotherapy, 166Ho-DOTMP) is an investigational radiopharmaceutical that delivers radiation directly to cancer cells in the bone and bone marrow.
- Trial name
- NCT00083564
- Testing
- STR(TM) (Skeletal Targeted Radiotherapy, Holmium-166-DOTMP)
- Where
- 21 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Poniard Pharmaceuticals
Multiple Myeloma
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
- Trial name
- NCT01838512
- Where
- 130 sites in United States, Canada and 4 more
- Volunteers
- 2,555 people
- Sponsor
- Bristol-Myers Squibb
Relapsed and Refractory Multiple Myeloma
Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability and overall response rate of carfilzomib in combination with dexamethasone for the treatment of multiple myeloma in China.
- Trial name
- NCT03029234
- Testing
- Dexamethasone, Carfilzomib
- Where
- 17 sites in China
- Volunteers
- 126 people
- Sponsor
- Amgen
Multiple Myeloma
PRospective Multiple Myeloma Impact Study
This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in Multiple Myeloma patients.
- Trial name
- PROMMIS (NCT02911571)
- Testing
- MMprofiler SKY92 gene signature
- Where
- 9 sites in United States
- Volunteers
- 250 people
- Sponsor
- SkylineDx
Relapsed or Refractory Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment.
- Trial name
- NCT05927571
- Testing
- Cevostamab, Elranatamab, Tocilizumab
- Where
- 14 sites in Australia, Israel and 1 more
- Volunteers
- 120 people
- Sponsor
- Genentech, Inc.
Multiple Myeloma
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
To evaluate the best overall response rate, safety and tolerability of carfilzomib in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT00530816
- Testing
- carfilzomib
- Where
- 30 sites in United States, Canada
- Volunteers
- 164 people
- Sponsor
- Amgen
Multiple Myeloma
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in patients with "relapsed or refractory multiple myeloma" (hereinafter referred to as "relapsed or refractory MM") who have…
- Trial name
- NCT02922543
- Where
- Japan
- Volunteers
- 361 people
- Sponsor
- Celgene
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or…
- Trial name
- NCT06433947
- Testing
- OPN-6602, Dexamethasone
- Where
- 12 sites in United States
- Volunteers
- 130 people
- Sponsor
- Opna Bio LLC
Multiple Myeloma
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in…
- Trial name
- UPFRONT (NCT00507416)
- Testing
- Bortezomib, Dexamethasone, Melphalan
- Where
- 235 sites in United States, Puerto Rico
- Volunteers
- 502 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
The purpose of this study is to evaluate the rate of response (how effectively treatment is working) with signs of potential cure at 5 years after the start of induction treatment.
- Trial name
- aMMbition (NCT06577025)
- Testing
- Cilta-cel, Talquetamab, Daratumumab
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 43 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects
TQB2934 is an anti-CD3(Early T Cell Marker)×BCMA (B cell maturation antigen) double-specific antibody，and the isoform is IgG1 (Native Immunoglobulin G1), which at one end binds to the CD3 receptor on the surface of T cells ,and…
- Trial name
- NCT05646758
- Testing
- TQB2934 injection
- Where
- 7 sites in China
- Volunteers
- 140 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Multiple Myeloma
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
- Trial name
- NCT03448978
- Testing
- Descartes-08, Fludarabine, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Cartesian Therapeutics
Multiple Myeloma
CT Antigen TCR-Engineered T Cells for Myeloma
This study will enroll patients with multiple myeloma who have received prior therapy for their disease but their disease has progressed or relapsed.
- Trial name
- NCT01892293
- Testing
- Treatment with NY-ESO-1c259-modified T cells
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Adaptimmune
Multiple Myeloma
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy, dose-escalation and dose expansion study. Forimtamig will be administered to participants with r/r MM for whom no standard-of-care treatment exists or…
- Trial name
- NCT04557150
- Testing
- Forimtamig
- Where
- 20 sites in Australia, Belgium and 7 more
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
A Study of Real Life Treatment for Multiple Myeloma (MM)
The main aim of this study is to learn how long it takes for people with MM to have a relapse after their first treatment. Not all participants will have a relapse during the study.
- Trial name
- LEADER (NCT04985643)
- Where
- 24 sites in Russia
- Volunteers
- 357 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.